ABBV AbbVie Earnings and EPS analysis
- Stocks
- Healthcare
- NYSE: ABBV
- Earnings
EPS in 2025 (TTM): $1.33
Last Report Period Date: Sep 30, 2025
As of November this year, based on AbbVie's most recent financial report, the company's trailing twelve months EPS is $1.33. During 2024, ABBV reported a per-share earnings of $2.4, which shows a decline compared to the EPS of $2.73 recorded in 2023. AbbVie's EPS for the quarterly period ending on Sep 30, 2025 came in at $0.1.
ABBV earnings history
The yearly earnings per share during 2024 was $2.4, a decline of 12.1% compared to $2.73 recorded in 2023. Over the quarter ending Sep 30, 2025, the earnings per share came in at $0.1, reflecting a 88.6% decline compared to the same quarter a year earlier. As of September 2025, the TTM EPS is $1.33. During 2023, the annual earnings per share was $2.73, representing a decrease of 58.9% compared to 2022.
ABBV EPS growth
AbbVie has recorded a decline in earnings per share of 88.6% in the past 12 months (YoY, quarterly). During the past three years, ABBV registered an average yearly EPS growth of -28.2%. AbbVie had an average annual EPS growth of -14.7% in the last five years. Over the last decade, ABBV had an average annual earnings per share growth of 8%.
ABBV Earnings Waterfall
ABBV Earnings vs Peers
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BIIB Biogen Inc | 13.96 | 39.8% | 2.4% | -18.7% |
| PFE Pfizer Inc | 14.31 | 273.7% | -28.7% | -13.2% |
| BMY Bristol Myers Squibb Co | 15.65 | -213.7% | N/A | N/A |
| GILD Gilead Sciences Inc | 24.27 | -91.6% | -57.5% | -38.3% |
| AMGN Amgen Inc | 24.55 | -39.3% | -9.7% | -10.1% |
| AZN Astrazeneca plc | 30.28 | 18.2% | 284.3% | 34.3% |
| NBIX Neurocrine Biosciences Inc | 35.67 | 32.8% | 53% | 53.4% |
| LLY ELI LILLY & Co | 45.18 | 102.1% | 24.1% | 5.7% |
| ABBV AbbVie Inc | 162.98 | -12.1% | -28.2% | -14.7% |
All data is based on quarterly TTM periods, unless otherwise specified.